Evidence Summary
What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide thisA combination of drugs reduces lower urinary tract symptoms in men
Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64:228-43.
Review question
Does a combination of drugs reduce lower urinary tract symptoms in men better than one drug alone?
Background
Lower urinary tract symptoms include the need to urinate (“pee” or “pass water”) more often than usual or right away, to urinate often at night, difficulty urinating, pain when urinating, and difficulty stopping urinating. These symptoms often occur in men with enlarged prostates and become more common as men get older.
Different drugs can be used to treat lower urinary tract symptoms. Combining different drugs might be better than any single drug alone for treating these symptoms.
How the review was done
The researchers did a systematic review, searching for studies that were published up to March 2012. They found 15 randomized controlled trials. The most consistent results came from 5 trials.
The trials included more than 9,600 men, with an average age of 62 to 66 years.
A combination of alpha-blockers plus 5-alpha reductase inhibitors was compared with either drug alone or with placebo. Examples of alpha-blockers include terazosin (Hytrin®), alfuzosin (Uroxatral®), doxazosin (Cardura®), and tamsulosin (Flomax ®). Examples of 5-alpha reductase inhibitors are finasteride (Propecia® or Proscar®) and dutasteride (Avodart®).
The trials looked at effects on lower urinary tract symptoms for up to 1 year or for longer periods (2 to 6 years).
What the researchers found
After 6 months to 1 year, a combination of alpha-blockers plus 5-alpha-reductase inhibitors:
- reduced symptoms more than placebo;
- reduced symptoms more than 5-alpha reductase inhibitors alone; but
- did not reduce symptoms more than alpha-blockers alone.
After 2 to 6 years, a combination of alpha-blockers plus 5-alpha reductase inhibitors reduced symptoms more than:
- placebo;
- 5-alpha reductase inhibitors alone; and
- alpha-blockers alone.
Conclusions
In men with lower urinary tract symptoms, a combination of alpha-blockers plus 5-alpha reductase inhibitors reduces short-term symptoms more than 5-alpha reductase inhibitors alone. It also reduces long-term symptoms more than either drug alone.
Combination of alpha-blockers plus 5-alpha reductase inhibitors vs control treatment for lower urinary tract symptoms in men
| Control treatment | Short term (6 months to 1 year) | Long term (2 to 6 years) |
| Placebo | Fewer symptoms with combination treatment | Fewer symptoms with combination treatment |
| 5-alpha reductase inhibitors alone | Fewer symptoms with combination treatment | Fewer symptoms with combination treatment |
| Alpha-blockers alone | No difference between combination treatment and control treatment | Fewer symptoms with combination treatment |
Related Topics
Glossary
A type of drug that affects the hormones that affect the prostate. They can be used to treat urinary symptoms and an enlarged prostrate.
A type of drug that relaxes certain muscles. They can be used to treat high blood pressure (by relaxing blood vessels to help blood flow). They are also used to treat urinary problems, often related to an enlarged prostate in men.
A harmless, inactive, and simulated treatment.
Studies where people are assigned to one of the treatments purely by chance.
A comprehensive evaluation of the available research evidence on a particular topic.
Related Evidence Summaries
-
Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women
Cochrane Database of Systematic Reviews (2011) -
Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse.
Cochrane Database Syst Rev (2016) -
Screening for prostate cancer
Cochrane Database of Systematic Reviews (2013)
Register for free access to all Professional content
RegisterOur Content
About
Support for the Portal is largely provided by the Labarge Optimal Aging Initiative. AGE-WELL is a contributing partner. Help us to continue to provide direct and easy access to evidence-based information on health and social conditions to help you stay healthy, active and engaged as you grow older. Donate Today.
